Payment overview · 2025
General Payments
$249.40
14 reported records · 9 companies
Healthcare provider profile · identity verified
Jonathan Pike, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GREAT BEND, KS · NPI 1891176707
Verified facts
What the public records show
CMS Open Payments records show Jonathan Pike, M.D. received $249.40 in general payments during 2025 across 14 reported records.
Amgen Inc. accounted for 38.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $96.55 | 38.7% | 6 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $31.95 | 12.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$27.75 | 11.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.91 | 8.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.63 | 7.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.44 | 6.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.00 | 5.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.54 | 5.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.63 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $249.40 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $66.31 | 4 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $31.95 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.24 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.24 | 2 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $27.75 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 18 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 551 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 419 | 99 |
| Lisinopril | Lisinopril | 400 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 335 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 322 | 86 |
| Losartan Potassium | Losartan Potassium | 307 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 300 | 68 |
| Metformin Hcl | Metformin Hcl | 259 | 57 |
| Furosemide | Furosemide | 234 | 41 |
| Potassium Chloride | Potassium Chloride | 221 | 44 |
| Gabapentin | Gabapentin | 169 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 166 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 44 |
| Simvastatin | Simvastatin | 155 | 37 |
| Omeprazole | Omeprazole | 151 | 43 |
| Meloxicam | Meloxicam | 141 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 41 |
| Spironolactone | Spironolactone | 124 | 21 |
| Allopurinol | Allopurinol | 123 | 31 |
| Metformin Hcl Er | Metformin Hcl | 121 | 32 |
| Ozempic | Semaglutide | 119 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 21 |
| Prednisone | Prednisone | 114 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 110 | 20 |
| Tramadol Hcl | Tramadol Hcl | 110 | 25 |
| Carvedilol | Carvedilol | 107 | 23 |
| Sertraline Hcl | Sertraline Hcl | 99 | 22 |
| Finasteride | Finasteride | 98 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 20 |
| Montelukast Sodium | Montelukast Sodium | 94 | 20 |
| Glimepiride | Glimepiride | 87 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 13 |
| Warfarin Sodium | Warfarin Sodium | 83 | 15 |
| Eliquis | Apixaban | 80 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 79 | 13 |
| Lorazepam | Lorazepam | 77 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 14 |
| Trazodone Hcl | Trazodone Hcl | 74 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 16 |
| Donepezil Hcl | Donepezil Hcl | 70 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 17 |
| Cephalexin | Cephalexin | 69 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 17 |
| Bumetanide | Bumetanide | 64 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 15 |
| Alendronate Sodium | Alendronate Sodium | 59 | 14 |
| Azithromycin | Azithromycin | 55 | 47 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 14 |
| Bupropion Xl | Bupropion Hcl | 50 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 12 |
| Trulicity | Dulaglutide | 44 | suppressed |
| Alprazolam | Alprazolam | 43 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 14 |
| Ezetimibe | Ezetimibe | 41 | 14 |
| Digoxin | Digoxin | 38 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Klor-Con M20 | Potassium Chloride | 36 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 19 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | 12 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 17 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Cartia Xt | Diltiazem Hcl | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $249.40 · 14 records | Amgen Inc. | EVENITY, GEMTESA, INTELLIS ADAPTIVESTIM, LEQVIO, OTEZLA, Prolastin-C Liquid, REPATHA, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error